OS Therapies completes $5.25M registered direct offering, expects $4M non-dilutive funds from UK subsidiary

OS Therapies Inc

Gross proceeds $5.25M; net proceeds ~$4.7M from offering of 2.5M shares (or pre-funded warrants) and 3.8M common warrants at $1.40/share.
Expects ~$2M VAT refunds from UK sub. in Q2 2026 and ~$2M R&D tax credits in H2 2026.
Combined funding expected to extend cash runway into 2027.
Targets OST-HER2 regulatory approvals (US FDA, UK MHRA, EU EMA) in H2 2026.
90-day lockup on further equity issuance; Ceros received 7% fee and warrants at $1.54.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

OS Therapies Inc entered into Purchase Agreement with purchasers identified on the signature pages thereto (effective 2026-03-31).

Action: entry
Agreement: equity purchase
Counterparty: purchasers identified on the signature pages thereto
Effective: 2026-03-31

Exact text from the filing

On March 31, 2026, OS Therapies Incorporated (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers identified on the signature pages thereto (the “Purchasers”), pursuant to which the Company offered for sale to the Purchasers in a registered direct offering (the “Offering”) an aggregate of 2,505,073 shares of its common stock and, in lieu thereof, pre-funded warrants to purchase up to 1,250,893 shares of its common stock (the “pre-funded warrants”), and accompanying warrants to purchase up to 3,755,966 shares of its common stock (the “common warrants”).

View on SEC.gov

Browse all material agreements →

OS Therapies Inc filing history →

Source: SEC EDGAR

accession 0001213900-26-039529

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.